Baranowski Lyn

Chief Executive Officer

Baranowski Lyn has filed 1 SEC Form 4 filing (7 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 19, 2026.

On the most recent filing, Baranowski Lyn is listed as Chief Executive Officer at Avalyn Pharma Inc. Inside the rolling window, Baranowski Lyn reported no open-market purchases and 2 open-market sales totaling $1.5M in AVLN. The largest disclosed transaction in the window is a sale of 45,300 AVLN shares on Nov 17, 2026, worth $1.3M.

Companies traded

Other insiders at AVLN

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.5M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
AVLNSale$1.3MNov 19SEC ↗
AVLNSale$201KNov 19SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Baranowski Lyn made?

Baranowski Lyn has filed 1 SEC Form 4 filing (7 transaction rows) across 1 company since 2026.

Which companies does Baranowski Lyn trade?

Baranowski Lyn has filed SEC Form 4 disclosures for 1 company, including AVLN.

When was Baranowski Lyn's most recent SEC Form 4 filing?

Baranowski Lyn's most recent SEC Form 4 filing on Tracefour is dated Nov 19, 2026.

What is Baranowski Lyn's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Baranowski Lyn is listed as Chief Executive Officer.

What is Baranowski Lyn's total buy and sell value in the current window?

Inside the rolling retention window, Baranowski Lyn bought $0 and sold $1.5M based on SEC Form 4 filings.

What was Baranowski Lyn's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 45,300 AVLN shares on 2026-11-17, worth $1.3M, per SEC Form 4 filings.